APA
Modvig S., Madsen H. O., Siitonen S. M., Rosthøj S., Tierens A., Juvonen V., Osnes L. T. N., Vålerhaugen H., Hultdin M., Thörn I., Matuzeviciene R., Stoskus M., Marincevic M., Fogelstrand L., Lilleorg A., Toft N., Jónsson O. G., Pruunsild K., Vaitkeviciene G., Vettenranta K., Lund B., Abrahamsson J., Schmiegelow K. & Marquart H. V. (2020). Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. : Leukemia.
Chicago
Modvig S, Madsen H O, Siitonen S M, Rosthøj S, Tierens A, Juvonen V, Osnes L T N, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson O G, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K and Marquart H V. 2020. Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. : Leukemia.
Harvard
Modvig S., Madsen H. O., Siitonen S. M., Rosthøj S., Tierens A., Juvonen V., Osnes L. T. N., Vålerhaugen H., Hultdin M., Thörn I., Matuzeviciene R., Stoskus M., Marincevic M., Fogelstrand L., Lilleorg A., Toft N., Jónsson O. G., Pruunsild K., Vaitkeviciene G., Vettenranta K., Lund B., Abrahamsson J., Schmiegelow K. and Marquart H. V. (2020). Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. : Leukemia.
MLA
Modvig S, Madsen H O, Siitonen S M, Rosthøj S, Tierens A, Juvonen V, Osnes L T N, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson O G, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K and Marquart H V. Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. : Leukemia. 2020.